Ainos, Inc. (AIMD)

NASDAQ: AIMD · IEX Real-Time Price · USD
0.813
-0.016 (-1.98%)
Feb 26, 2024, 12:17 PM EST - Market open

Company Description

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.

The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.

It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.

The company was incorporated in 1984 and is based in San Diego, California.

Ainos, Inc.
Ainos logo
Country United States
Founded 1984
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Chun-Hsien Tsai

Contact Details

Address:
Ainos, Inc., 8880 Rio San Diego Drive Suite 800
San Diego, California 92108
United States
Phone 858-869-2986
Website ainos.com

Stock Details

Ticker Symbol AIMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001014763
CUSIP Number 00902F105
ISIN Number US00902F3038
Employer ID 75-1974352
SIC Code 2834

Key Executives

Name Position
Chun-Hsien Tsai Chairman of Board, President and Chief Executive Officer
Lawrence Kennedy Lin Executive Vice President of Operations
Meng-Lin Sung Chief Financial Officer
Chih-Heng Lu Director of Corporate Developoment

Latest SEC Filings

Date Type Title
Feb 15, 2024 10-Q/A [Amend] Quarterly report
Feb 5, 2024 8-K Current Report
Jan 29, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 25, 2024 8-K Current Report
Jan 12, 2024 8-K Current Report
Jan 2, 2024 8-K Current Report
Dec 22, 2023 8-K Current Report
Dec 18, 2023 EFFECT Notice of Effectiveness
Dec 15, 2023 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Dec 14, 2023 8-K Current Report